Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Cash from Financing Activities (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Cash from Financing Activities for 11 consecutive years, with $9.9 million as the latest value for Q3 2025.

  • Quarterly Cash from Financing Activities rose 579787.3% to $9.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $9.9 million through Dec 2025, down 34.2% year-over-year, with the annual reading at $9.9 million for FY2025, 34.2% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $9.9 million at Marker Therapeutics, up from $100.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $52.7 million in Q1 2021, with the low at -$100743.0 in Q2 2021.
  • Average Cash from Financing Activities over 5 years is $5.2 million, with a median of $49096.0 recorded in 2024.
  • Peak annual rise in Cash from Financing Activities hit 579787.3% in 2025, while the deepest fall reached 99.78% in 2025.
  • Over 5 years, Cash from Financing Activities stood at -$100743.0 in 2021, then skyrocketed by 237.54% to $138557.0 in 2022, then crashed by 96.29% to $5135.0 in 2023, then skyrocketed by 289985.9% to $14.9 million in 2024, then tumbled by 33.78% to $9.9 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $9.9 million, $100.0, and $505.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.